KPRX

Kiora Pharmaceuticals Inc

KPRX, USA

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

https://www.kiorapharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KPRX
stock
KPRX

RSI Check: Can Appian Corporation stock resist market sell offs - 2025 Market Outlook & Accurate Entry and Exit Point Alerts moha.gov.vn

Read more →
KPRX
stock
KPRX

Kiora Pharma (NASDAQ: KPRX) wins US patent amid Phase 2 KIO-104 eye study Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$12

Analyst Picks

Strong Buy

0

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.41

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

0.12 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.09 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.33

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 28.06% of the total shares of Kiora Pharmaceuticals Inc

1.

AIGH Capital Management, LLC

(6.301%)

since

2025/06/30

2.

Nantahala Capital Management, LLC

(6.1486%)

since

2025/06/30

3.

Stonepine Capital Management Llc

(5.1842%)

since

2025/06/30

4.

ADAR1 Capital Management LLC

(4.8671%)

since

2025/06/30

5.

Velan Capital Investment Management LP

(3.5597%)

since

2025/06/30

6.

Geode Capital Management, LLC

(0.5409%)

since

2025/06/30

7.

UBS Group AG

(0.5139%)

since

2025/06/30

8.

Fidelity Extended Market Index

(0.4045%)

since

2025/07/31

9.

Fidelity Series Total Market Index

(0.1004%)

since

2025/07/31

10.

NT Ext Equity Mkt Idx Fd - L

(0.0776%)

since

2025/06/30

11.

Northern Trust Extended Eq Market Idx

(0.0776%)

since

2025/06/30

12.

Bridgeway Omni Small-Cap Value

(0.0582%)

since

2025/06/30

13.

Bridgeway Omni Small-Cap Value N

(0.0582%)

since

2025/06/30

14.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0546%)

since

2025/07/31

15.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0219%)

since

2025/06/30

16.

Fidelity Total Market Index

(0.0218%)

since

2025/07/31

17.

Spartan Total Market Index Pool G

(0.0196%)

since

2025/07/31

18.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0185%)

since

2024/12/31

19.

Tower Research Capital LLC

(0.0128%)

since

2025/06/30

20.

SBI Securities Co Ltd

(0.0075%)

since

2025/06/30

21.

Spartan Extended Market Index Pool F

(0.0029%)

since

2025/07/31

22.

BlackRock Inc

(0.0017%)

since

2025/06/30

23.

Citigroup Inc

(0.001%)

since

2025/06/30

24.

Goss Wealth Management LLC

(0.0006%)

since

2025/06/30

25.

Bank of America Corp

(0.0006%)

since

2025/06/30

26.

NT Ext Equity Mkt Idx Fd - NL

(0.0003%)

since

2025/06/30

27.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0002%)

since

2025/06/30

28.

Advisor Group Holdings, Inc.

(0.0001%)

since

2025/06/30

29.

Activest Wealth Management

(0.0001%)

since

2025/06/30

30.

State St US Extended Mkt Indx NL Cl C

(0.0001%)

since

2025/08/31

31.

SSgA U.S. Total Market Index Strategy

(0.0001%)

since

2025/03/31

32.

Sabby Management LLC

(0%)

since

2025/06/30

33.

Citadel Advisors Llc

(0%)

since

2025/06/30

35.

U.S. Bancorp

(0%)

since

2025/03/31

36.

Rosalind Advisors, Inc.

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.01

EPS Estimate

-0.72

EPS Difference

0.73

Surprise Percent

101.3889%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(9.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Strong Net-Net(7.5)
Quality
Moderate Quality(5)
Value
Undervalued(8)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.